Other therapeutic strategies not focused on direct NRF2 inhibition may be considered; i.e., the exploration of indirect methods of inhibition, such as upstream and/or downstream protein kinases, can be an open new therapeutic field for lung cancer patients. The gene discussed is NFE2L2; the disease is lung carcinoma.